Very late activation antigen-4 (VLA-4) antagonists

Progress in Respiratory Research

Volumn 39, Issue , 2010, Pages 169-173

  Vanderslice, Peter ^a   Woodside, Darren G ^a  

^a TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956492314     PISSN: 14222140     EISSN: 16623932     Source Type: Book Series    
DOI: 10.1159/000320816     Document Type: Article

References (51)

1. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110(6): 673-87.
2. Hemler ME, Huang C, Takada Y, Schwarz L, Strominger JL, Clabby ML. Characterization of the cell surface heterodimer VLA-4 and related peptides. J Biol Chem 1987, 262(24): 11478-85.
3. Bochner BS, Luscinskas FW, Gimbrone MA, Jr. et al. Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med 1991, 173(6): 1553-7.
4. Kubes P, Niu X-F, Smith CW, Kehrli ME, Reinhardt PH, Woodman R. A novel beta1-dependent adhesion pathway on neutrophils: a mechanism invoked by dihydrocytochalasin B or endothelial transmigration. FASEB J 1995, 9(11): 1103-11.
5. Issekutz TB, Miyasaka M, Issekutz AC. Rat blood neutrophils express very late antigen 4 and it mediates migration to arthritic joint and dermal inflammation. J Exp Med 1996, 183(5): 2175-84.
6. Maddox L, Schwartz DA. The pathophysiology of asthma. Annu Rev Med 2002, 53(4): 477-98.
7. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000, 343(4): 269-80.
8. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007, 7(9): 678-89.
9. Laudanna C, Kim JY, Constantin G, Butcher E. Rapid leukocyte integrin activation by chemokines. Immunol Rev 2002, 186: 37-46.
10. Berlin C, Bargatze RF, Campbell JJ et al. alpha4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 1995, 80(3): 413-22.
11. Elices MJ, Osborn L, Takada Y et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4/Fibronectin binding site. Cell 1990, 60(4): 577-84.
12. Wayner EA, Garcia-Pardo A, Humphries MJ, McDonald JA, Carter WG. Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J Cell Biol 1989, 109(3): 1321-30.
13. Cybulsky MI, Gimbrone MA, Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991, 251(4995): 788-91.
14. Elices MJ, Tsai V, Strahl D et al. Expression and functional significance of alternatively spliced CS1 fibronectin in rheumatoid arthritis microvasculature. J Clin Invest 1994, 93(1): 405-16.
15. Berlin C, Berg EL, Briskin MJ et al. alpha4beta7 integrin mediates lymphocyte binding to the mucosal vascular addressin madcam-1. Cell 1993, 74(1): 185-95.
16. Newham P, Craig SE, Seddon GN et al. Alpha4 integrin binding interfaces on VCAM-1 and MAdCAM-1. Integrin binding footprints identify accessory binding sites that play a role in integrin specificity. J Biol Chem 1997, 272(31): 19429-40.
17. Spring FA, Parsons SF, Ortlepp S et al. Intercellular adhesion molecule-4 binds alpha(4)beta(1) and alpha(V)-family integrins through novel integrin-binding mechanisms. Blood 2001, 98(2): 458-66.
18. Briskin M, Winsor-Hines D, Shyjan A et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997, 151(1): 97-110.
19. Cunningham SA, Rodriguez JM, Arrate MP, Tran TM, Brock TA. JAM2 interacts with alpha4beta1. Facilitation by JAM3. J Biol Chem 2002, 277(31): 27589-92.
20. Altevogt P, Hubbe M, Ruppert M et al. The alpha 4 integrin chain is a ligand for alpha 4 beta 7 and alpha 4 beta 1. J Exp Med 1995, 182(2): 345-55.
21. Burkly LC, Jakubowski A, Newman BM, Rosa MD, Chi-Rosso G, Lobb RR. Signaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD3-dependent T cell proliferation. Eur J Immunol 1991, 21(11): 2871-5.
22. Shimizu Y, Seventer GAV, Horgan KJ, Shaw, S. Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. J Immunol 1990, 145(1): 59-67.
23. Woodside DG, Kram RM, Mitchell JS et al. Contrasting roles for domain 4 of VCAM-1 in the regulation of cell adhesion and soluble VCAM-1 binding to integrin alpha4beta1. J Immunol 2006, 176(8): 5041-9.
24. Hojo M, Maghni K, Issekutz TB, Martin JG. Involvement of alpha-4 integrins in allergic airway responses and mast cell degranulation in vivo. Am J Respir Crit Care Med 1998, 158(4): 1127-33.
25. Securities and Exchange Commission Form 10K Encysive Pharmaceuticals Inc. Houston, TX: Encysive Pharmaceuticals, Inc; March 16, 2007
26. Biogen Idec and Elan announce availability of Tysabri® for the treatment of relapsing forms of multiple sclerosis [news release]. Cambridge, MA and Dublin, Ireland: Biogen Idec and Elan; July 24, 2006. http://www. biogenidec.com/news/BiogenIDECPR-136.htm. Accessed August 31, 2007.
27. FDA approves Tysabri® for the treatment of moderate-to-severe Crohn's disease [news release]. Dublin, Ireland and Cambridge, MA: Elan and Biogen Idec; January 14, 2008. http://www.biogenidec.com/news/BiogenIDECPR- 2008-05.htm. Accessed February 27, 2008
28. Roche nine-month sales hit record high [news release]. Basel, Switzerland: F. Hoffmann-La Roche Ltd; October 17, 2006. http://www.roche.com/ medcor- 2006-10-17. Accessed August 31, 2007
29. FDA places clinical hold on studies with alpha-4 integrin antagonists. Includes MS and Crohn's disease studies with GlaxoSmithKline/Tanabe compound [news release]. Osaka, Japan: Tanabe Seiyaku Co. Ltd; March 16, 2005. http://www.mtpharma.co.jp/e/release/nr/tanabe/2005/pdf/20050316-e.pdf. Accessed August 31, 2007
30. UCB and Biogen Idec's oral VLA-4 antagonist enters phase II development for multiple sclerosis [news release]. Brussels, Belgium and Cambridge, MA: UCB and Biogen Idec; June 26, 2007. http://www.biogenidec.com/news/ BiogenIDECPR-171.htm. Accessed August 31, 2007.
31. ATL1102 phase IIa multiple sclerosis trial update [news release]. Victoria, Australia: Antisense Therapeutics Limited; June 22, 2007. http://www.antisense.com.au/!upload-files/attachment/asx%2007%20June%202 2%20ATL1102%20Trial%20Update.pdf. Accessed August 31, 2007
32. Presentation of asthma data at American Thoracic Society Meeting: Inhaled antisense drug targeting VLA-4 [news release]. Victoria, Australia: Antisense Therapeutics Limited; May 23, 2005. http://www.antisense.com.au/ !upload-files/attachment/401.pdf. Accessed August 31, 2007
33. Elan reports third quarter. 2006 financial results [news release]. Dublin, Ireland: Elan Corporation, plc; October 25, 2006. http://www.elan.com/ News/ 2006/20061025.asp. Accessed August 31, 2007
34. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354(9): 899-910.
35. Targan SR, Feagan BG, Fedorak RN. et al. Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE Trial. Gastroenterology 2007, 132(5): 1672-83.
36. FDA grants accelerated approval of Tysabri®, formerly Antegren®, for the treatment of multiple sclerosis [news release]. Cambridge, MA, San Diego, CA, and Dublin, Ireland: Biogen Idec and Elan; November 23, 2004. http:// www.biogenidec.com/news/BiogenIDECPR-062.htm. Accessed August 31, 2007.
37. Henderson W.R, Chi EY, Albert RK et al. Blockade of CD49d (alpha4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J Clin Invest 1997, 100(12): 3083-92.
38. Pretolani M, Ruffie C, Lapa e Silva JR, Joseph D, Lobb RR, Vargaftig BB. Antibody to very late activation antigen 4 prevents antigen-induced bronchial hyperreactivity and cellular infiltration in the guinea pig airways. J Exp Med 1994, 180(3): 795-805.
39. Metzger WJ. Therapeutic approaches to asthma based on VLA-4 integrin and its counter receptors. Springer Semin Immunopathol 1995, 16(4): 467-78.
40. Abraham WM, Sielczak MW, Ahmed A. et al. Alpha 4-integrins mediate antigeninduced late bronchial responses and prolonged airway hyperresponsiveness in sheep. J Clin Invest 1994, 93(2): 776-87.
41. Abraham, WM, Gill A, Ahmed A. et al. A small-molecule, tight-binding inhibitor of the integrin alpha(4)beta(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am J Respir Crit Care Med 2000, 162(2, Pt.1): 603-11.
42. Koo GC, Shah K, Ding GJ. et al. A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation. Am J Respir Crit Care Med 2003, 167(10): 1400-9.
43. Kudlacz E, Whitney C, Andresen C. et al. Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule alpha4beta1 antagonists. J Pharmacol Exp Ther 2002, 301(2): 747-52.
44. Drug Development Pipeline: BIO-1211 (company communication). Cambridge, MA: Biogen Idec; March 30, 2000.
45. Diamant Z, Kuperus J, Baan R. et al. Effect of a very late antigen-4 receptor antagonist on allergen-induced airway responses and inflammation in asthma. Clin Exp Allergy 2005, 35(8): 1080-7.
46. Norris V, Choong L, Tran D. et al. Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol 2005, 116(4): 761-7.
47. Drug development update (company communication). Middlesex, UK: GlaxoSmithKline plc; December 8, 2003.
48. Rames AD et al. R411 treatment reduces asthma exacerbations and attenuates FEV1 fall following steroid withdrawal in moderate asthma. Eur Respir J 2005, 26(Suppl. 49): Abst P1721.
49. Biogen Idec and Elan announce voluntary suspension of Tysabri® [news release]. Cambridge, MA and Dublin, Ireland: Biogen Idec and Elan; February 28, 2005. http://www.biogenidec.com/news/BiogenIDECPR-069.htm. Accessed August 31, 2007.
50. Yousry TA, Major EO, Ryschkewitsch C. et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006, 354(9): 924-33.
51. Bednarczyk JL, McIntyre BW. A monoclonal antibody to VLA-4 a-chain (CDw49d) induces homotypic lymphocyte aggregation. J Immunol 1990, 144(3): 777-84.